NewAmsterdam Pharma (NASDAQ:NAMS) Short Interest Update

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) was the target of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 5,340,000 shares, an increase of 23.0% from the March 15th total of 4,340,000 shares. Based on an average daily trading volume, of 996,300 shares, the days-to-cover ratio is currently 5.4 days. Currently, 9.4% of the company's stock are sold short.

NewAmsterdam Pharma Stock Up 0.3 %

NASDAQ NAMS traded up $0.05 during trading on Friday, hitting $17.52. The company's stock had a trading volume of 345,323 shares, compared to its average volume of 590,491. NewAmsterdam Pharma has a 52 week low of $14.06 and a 52 week high of $27.29. The firm has a market cap of $1.92 billion, a P/E ratio of -6.74 and a beta of -0.01. The firm has a 50 day moving average price of $19.66 and a 200 day moving average price of $21.20.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.47). The company had revenue of $12.77 million for the quarter, compared to analyst estimates of $3.30 million. On average, equities analysts expect that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

Insider Activity

In other NewAmsterdam Pharma news, Director James N. Topper bought 4,005 shares of NewAmsterdam Pharma stock in a transaction on Tuesday, March 4th. The stock was purchased at an average cost of $21.02 per share, for a total transaction of $84,185.10. Following the completion of the purchase, the director now directly owns 3,012,434 shares of the company's stock, valued at $63,321,362.68. The trade was a 0.13 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Louise Frederika Kooij sold 150,000 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the completion of the sale, the chief accounting officer now directly owns 15,000 shares of the company's stock, valued at $305,550. This represents a 90.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 19.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in NAMS. GF Fund Management CO. LTD. acquired a new stake in NewAmsterdam Pharma during the fourth quarter worth about $50,000. National Bank of Canada FI bought a new stake in shares of NewAmsterdam Pharma in the 4th quarter worth approximately $51,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of NewAmsterdam Pharma during the 4th quarter worth approximately $80,000. Barclays PLC increased its position in shares of NewAmsterdam Pharma by 1,813.4% during the third quarter. Barclays PLC now owns 7,596 shares of the company's stock valued at $126,000 after purchasing an additional 7,199 shares during the period. Finally, Avanza Fonder AB acquired a new position in shares of NewAmsterdam Pharma in the first quarter valued at $127,000. Institutional investors own 89.89% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. UBS Group set a $41.00 price target on NewAmsterdam Pharma in a research report on Monday, March 3rd. HC Wainwright restated a "buy" rating and issued a $48.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Royal Bank of Canada reiterated an "outperform" rating and set a $40.00 price target on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Scotiabank boosted their price objective on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Thursday, February 27th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $42.00 price objective on shares of NewAmsterdam Pharma in a report on Tuesday, April 8th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, NewAmsterdam Pharma presently has an average rating of "Buy" and a consensus target price of $43.33.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.